White crystalline powder, soluble in methanol, ethanol, DMSO and other organic solvents, derived from dried near-ripe fruit of Evodia sclerosus.
Dehydroevodiamine is a novel alkaloid which displays butyrylcholinesterase inhibitory activity in vivo.
Dehydroevodiamine, a quinazoline alkaloid isolated from Evodiae Fructus, has antiarrhythmic effects on guinea pig ventricular myocytes. It inhibits LPS-induced expression of iNOS, COX-2, PGE2 and NF-κB in mouse macrophages.
Dehydroevodiamine has an antihypertensive and antitumor effects.
Dehydroevodiamine (0-50 μM; 2 hours) inhibits iNOS and COX-2 expression and prevents degradation of IκB-α in LPS induced RAW 264.7 macrophages. Dehydroevodiamine (0-50 μM; 2 hours) inhibits a LPS -induced increase in the iNOS and COX-2 mRNA expression.
Western Blot Analysis
| Cell Line: td> | RAW 264.7 macrophage cells |
| Concentration: | 10 μM, 30 μM, 50 μM |
| Incubation Time: | pretreated 2 hours |
| Result: | Reduced iNOS and COX-2 expression and increased IκB-α expression. |
RT-PCR
< td class="col1"> Cell Line: | RAW 264.7 macrophage cells |
| Concentration: | 10 μM, 30 μM, 50 μM | td>
| Incubation Time: | pretreated 2 hours |
| Result: | Reduced iNOS and COX-2 mRNA expression. |
| Target | Value |
NF-κB
() |
COX-2
() |
iNOS
() |
PGE2
() |
